EconomyEditor's PickNewsU.S. court voids $448 million award against AbbVie, AndroGel partner

1 year ago115 min
https://topinvestingtoday.com/wp-content/uploads/2021/12/cover-9-1280x813.jpg
imageStock Markets17 minutes ago (Sep 30, 2020 10:15AM ET)

(C) Reuters. A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange

(Reuters) – A federal appeals court on Wednesday threw out an order that had required AbbVie Inc (NYSE:ABBV) and a partner to disgorge $448 million in profit, in antitrust litigation accusing AbbVie of trying to illegally keep generic versions of its testosterone replacement drug AndroGel off the market.

Ruling in a case brought by the Federal Trade Commission, the 3rd U.S. Circuit Court of Appeals in Philadelphia said the lower court judge who ordered the disgorgement by AbbVie and Besins Healthcare Inc lacked authority under applicable federal law.

The appeals court also upheld an order finding AbbVie and Besins liable for monopolization, based upon its holding that they had filed a sham patent infringement lawsuit against Perrigo Co (NYSE:PRGO) to delay the launch of generic AndroGel.

It also reinstated other FTC claims, and returned the case to the lower court for further proceedings.

AbbVie and lawyers for Besins did not immediately respond to requests for comment. The FTC did not immediately respond to similar requests.

U.S. court voids $448 million award against AbbVie, AndroGel partner

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Leave a Reply

Your email address will not be published. Required fields are marked *